It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
-
The Role of Scientific Advisers in the English Patents Court
-
Trying to Make Sense of the Oracle of G 2/21: T 116/18 vs. T 681/21
-
Patent case: NanoString Technologies vs. 10x Genomics and President and Fellows of Harvard College, UPC
-
Patent case: Judgment no. 141/2023 dated 5 December 2023, Spain
Random Articles:
-
Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA
-
Fordham Conference 2015 – Patent Valuation
-
Union calls for strike at the EPO, first time since president António Campinos took office
-
Barcelona Courts approve Trade Secrets Protocol that may indirectly impact patent cases
-
Waters v. Agilent et al., Court of First Instance Paris (Tribunal de Grande Instance Paris), 14 Januari 2009
-
BPO v. AstraZeneca (II), Supreme Administrative Court (Bърховен касационен съд), 8 December 2010
-
Added matter, Amendments, Disclaimer, EPC, Germany, Netherlands, Opposition, Revocation, United Kingdom, Validity
Oxycodone – An Unfinished Battle and an Undisclosed Question
-
You Shall Not Lie – Part 2 -Courts Can Get Nasty
-
Is the Federal Patent Court obliged to appoint a technical expert?
-
Evasive answer, Federal Supreme Court (Bundesgericht), 23 May 2011